ClinicalTrials.Veeva

Menu

Predictors for ACS and Complexity of CAD

A

Assiut University

Status

Not yet enrolling

Conditions

Young Population
TG Index
TG/HDL-C Ratio

Treatments

Diagnostic Test: PCI

Study type

Observational

Funder types

Other

Identifiers

NCT07130188
Predictors for ACS

Details and patient eligibility

About

To evaluate the significance of the Triglyceride index and TG/HDL-C ratio as predictors of acute coronary syndromes in the young population

Full description

Cardiovascular disease (CVD) remains a major cause of morbidity and mortality worldwide, with a rising incidence of acute coronary syndromes (ACS) in young individuals under the age of 40. Early identification of at-risk individuals in this population is essential for implementing preventive strategies and reducing adverse outcomes【1,2】. Traditional risk factors such as hypertension, diabetes, smoking, and dyslipidemia are well-established; however, their predictive value in the young population is often limited【2】.

Recent studies have highlighted the significance of novel lipid-derived markers, particularly the triglyceride-glucose (TyG) index and the triglyceride-to-high-density lipoprotein cholesterol (TG/HDL-C) ratio, as potential predictors of insulin resistance, subclinical atherosclerosis, and cardiovascular events【1,3】. The TyG index and TG/HDL-C ratio are simple, cost-effective markers derived from routine laboratory parameters and have shown promising associations with metabolic syndrome, endothelial dysfunction, and coronary artery disease (CAD) severity【3,4】.

Despite emerging evidence in older adults, limited data exist regarding the utility of these markers in predicting ACS among the young population, where conventional risk scores often underestimate risk【4,5】. Early detection through these markers could improve risk stratification and guide preventive strategies.

This study aims to evaluate the significance of the TyG index and TG/HDL-C ratio as predictors of ACS in young adults, providing insight into their potential role in primary prevention

Enrollment

130 estimated patients

Sex

All

Ages

18 to 40 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Age 18-40 years. Confirmed diagnosis of ACS (STEMI, NSTEMI). Willingness to participate with informed consent.

Exclusion criteria

  • Age > 40 years old People with Previous ACS Patients known to have familial hyperlipidemia

Trial contacts and locations

0

Loading...

Central trial contact

Mohamed Osman Abdelhameed, Lecturer; Saleh Mohamed Saleh, Resident

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems